# Senseonics Holdings, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Senseonics Holdings, Inc.). ## Overview Senseonics Holdings, Inc. develops and commercializes the Eversense continuous glucose monitoring system for people with diabetes. The company is based in the United States and sells implantable CGM sensors, transmitters, and related components through healthcare and distribution channels in the U.S. and Europe. ## Products & services • Eversense implantable continuous glucose monitoring system • Disposable glucose sensor components • External transmitter and smart device connectivity • Related supplies, support, and patient training services - **Implantable CGM systems** (70%) — Eversense glucose monitoring systems that measure glucose continuously for diabetes management. - **Sensors and consumables** (20%) — Disposable sensor components and other recurring consumables used with the system. - **Transmitters and hardware** (7%) — External transmitter devices and related hardware used to read and transmit glucose data. - **Commercial support and services** (3%) — Training, patient support, and commercialization-related services tied to adoption and retention. - Eversense implantable continuous glucose monitoring system - Disposable glucose sensor components - External transmitter and smart device connectivity - Related supplies, support, and patient training services ## Customers Senseonics sells primarily to commercial partners, distributors, and healthcare channels that then place Eversense with patients and healthcare providers. End users are diabetes patients and their care teams, with recurring demand driven by sensor replacement and ongoing system use. The company also relies on healthcare professionals and payor coverage decisions because those influence adoption and repeat usage. - **Commercial distribution partners** (primary) — Partners that buy Eversense products for resale and commercialization support. - **Diabetes patients** (primary) — End users of the CGM system who drive recurring sensor consumption and retention. - **Healthcare providers** (secondary) — Clinics and prescribers that recommend, implant, and monitor the system. - **Payers and reimbursement systems** (secondary) — Insurers and coverage decision-makers that determine patient access and adoption. - Commercial distribution partners that resell Eversense to providers and patients - Healthcare providers that place the system with diabetes patients - Diabetes patients who use the system and replace sensors over time - Caregivers and clinicians who influence device selection and adherence - Payers and reimbursement stakeholders that affect patient access ## Geography Senseonics operates in the United States and in markets outside the United States, with revenue disclosed across those two primary regions. The company’s commercial footprint is tied to diabetes device adoption, reimbursement, and regulatory access in each market, which makes geography important to both distribution and market penetration. Its European business has also involved local commercial and tender arrangements, while U.S. commercialization has been central to the Eversense franchise. - **United States** (71.8%) — Three months ended March 31, 2025 - **Outside of the United States** (28.2%) — Three months ended March 31, 2025 - United States is the core commercial market for Eversense - Outside the United States includes European and other international sales - Revenue depends on diabetes device adoption and reimbursement by market - Commercial operations require local distribution and healthcare channel support ## Strategy Senseonics’ strategy centers on expanding adoption of Eversense, improving patient access, and strengthening commercialization control over its product. The company also focuses on payer coverage, patient retention, and product development such as Eversense 365 in the United States, because recurring sensor use and long-term adoption are central to the model. - **Grow Eversense adoption and retention** (short-term) — Recurring sensor demand depends on keeping patients on the platform. - **Expand payer coverage and patient access** (medium-term) — Reimbursement decisions materially affect device uptake and persistence. - **Advance next-generation CGM products** (medium-term) — Product improvements are needed to compete with larger CGM rivals. - **Control commercialization more directly** (short-term) — Owning more of the sales and distribution process can improve execution. - Expand Eversense adoption among diabetes patients and clinicians - Improve insurance coverage and patient access to support uptake - Strengthen commercialization and distribution control - Develop next-generation Eversense products such as Eversense 365 - Support retention through training, service, and patient programs ## Risks Senseonics faces concentration risk because a large share of revenue has historically depended on a small number of commercialization partners, especially Ascensia. It also competes in a fast-moving CGM market against larger device makers, while reimbursement, regulatory approvals, manufacturing execution, and patient retention all directly affect demand and recurring sensor sales. - **Dependence on Ascensia commercialization** [high] — A substantial portion of historical revenue came from one commercial partner. - **Competitive pressure in CGM** [high] — Dexcom, Abbott, and Medtronic have larger scale and broad market presence. - **Reimbursement and coverage risk** [high] — Patient uptake depends heavily on insurance coverage and payor policy. - **Manufacturing and distribution execution** [medium] — The product requires reliable sterilization, inventory handling, and delivery. - **Regulatory and product acceptance risk** [medium] — CGM adoption depends on approvals, certifications, and clinician confidence. - Revenue concentration with Ascensia can create customer dependency - CGM competition is intense and includes larger, well-funded rivals - Reimbursement changes can reduce patient access and adoption - Manufacturing, sterilization, and distribution issues can disrupt supply - Regulatory and product-performance issues can slow commercialization ## Accounting Revenue recognition is a key accounting area because Senseonics sells through distributors and also uses consignment arrangements where revenue is recognized only when a patient consumes the product. Variable consideration, including discounts and revenue-share arrangements, requires judgment and affects the timing and amount of reported revenue. Contract assets, contract liabilities, warranty reserves, inventory obsolescence, and stock-based compensation are also important estimates that can move reported results. - **Revenue recognition timing** — Can shift revenue between periods - **Variable consideration** — Affects net revenue and contract assets - **Contract assets and liabilities** — Can materially affect balance sheet presentation - **Inventory obsolescence and warranties** — Affects cost of sales and operating expenses - **Stock-based compensation** — Affects operating loss and diluted share metrics - Point-in-time revenue recognition for distributor sales - Consignment revenue recognized when product is consumed by a patient - Variable consideration and revenue-share estimates affect net revenue - Contract assets and liabilities reflect commercialization arrangements - Warranty, inventory, and clinical accrual estimates affect expenses --- *Last updated: 2026-04-29T04:58:03.261077+00:00*